Biopharmaceutical company
Appears in 3 stories · Last updated Oct 19, 2026
Developer of VQW-765; program on hold pending analysis
Vanda Pharmaceuticals' experimental anxiety drug failed its 546-patient Phase III trial, and the company has put the program on hold. VQW-765 matched placebo on a public-speaking stress test in adults with social anxiety disorder.
Updated Oct 19
Awaiting FDA discussion; plans sNDA for DSWPD
Vanda Pharmaceuticals said a late-stage trial of HETLIOZ (tasimelteon) shifted the timing of sleep onset 37.1 minutes earlier than placebo in adults with delayed sleep-wake phase disorder (DSWPD). The result was statistically significant (p=0.022), and 60% of treated patients advanced their sleep by at least 30 minutes, versus 15% on placebo.
Updated Oct 17
As of May 2026: Preparing commercial launch of Bysanti in H2 2026; raised full-year 2026 revenue guidance to $240–$290 million
The FDA approved Cobenfy for schizophrenia in September 2024—the first drug to treat the condition through muscarinic receptors rather than dopamine, a different approach than any approved in the previous 50 years. Bysanti (milsaperidone) followed in February 2026, cleared for both schizophrenia and bipolar I disorder. For the roughly 7 million Americans with these conditions, the treatment menu is wider than it was two years ago.
Updated May 29
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
